Fourth Affiliated Hospital of Guangxi Medical University
12
3
4
0
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 12 trials
25%
3 trials in Phase 3/4
0%
0 of 0 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma
Role: collaborator
Comparison of Safety and Efficacy of Detaenial Sigmoid Neobladder and Ileal Neobladder
Role: collaborator
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
Role: lead
Concurrent and Adjuvant Nimotuzumab Combined With Induction Chemotherapy Plus Chemoradiation in Nasopharyngeal Carcinoma
Role: lead
Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma
Role: collaborator
Transurethral Plasmakinetic Enucleation of Prostate Versus Transurethral Resection of Prostate
Role: collaborator
Efficacy of HIPEC in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery
Role: collaborator
Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer
Role: collaborator
Interleukin-10 Promoter-1082A/G Polymorphism and Idiopathic Recurrent Miscarriage Risk
Role: lead
Effectiveness of Acupuncture for Breast Cancer Related Lymphedema
Role: lead
Research on the Role of SLC1A5 in the Development of Esophageal Cancer
Role: lead
Efficacy and Safety of Wuling San on Breast Cancer-related Lymphedema
Role: lead
All 12 trials loaded